Paydirt
AG
Insider

Ansbert Gadicke

10% owner

Ansbert Gadicke (10% owner) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Aktis Oncology, Inc. (AKTS). Across 1 priced purchase filing, the average 21-session return was -20.7% from execution and -15.6% from disclosure (delay-adjusted; derived). The largest single filing was $20.0M of AKTS (1,112,777 sh × $18.00, as filed), executed Jan 12.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
-20.7%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-15.6%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
2d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$20.0M
shares × price, as filed
Last traded
Jan 12
Filed Jan 14

Median ADV $8.9M across their filed names

Open performance→
Volume by month
$20.0M$10.0M$0Oct 2024Apr 2025Oct 2025Apr 2026Jan 2026 · buys $20.0M
Buys $20.0M Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Healthcare 1 filing

Sector per market data · by filing · past 12 months

Most traded names
AKTS Aktis Oncology, Inc. AKTS · 1 buy · 0 sells 1 filing
Recent filings
AKTSPURCHASE Aktis Oncology, Inc. View filing → $20.0M
1,112,777 sh × $18.00
Exec Jan 12
Filed Jan 14 · 6:17 PM ET